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Abstract
Clostridium difficile, the most common cause of hospital-associated diarrhoea in developed
countries, presents major public health challenges. The high clinical and economic burden
from C. difficile infection (CDI) relates to the high frequency of recurrent infections caused
by either the same or different strains of C. difficile. An interval of 8 weeks after index infection is commonly used to classify recurrent CDI episodes. We assessed strains of C. difficile in
a sample of patients with recurrent CDI in Western Australia from October 2011 to July 2017.
The performance of different intervals between initial and subsequent episodes of CDI was
investigated. Of 4612 patients with CDI, 1471 (32%) were identified with recurrence. PCR
ribotyping data were available for initial and recurrent episodes for 551 patients. Relapse
(recurrence with same ribotype (RT) as index episode) was found in 350 (64%) patients
and reinfection (recurrence with new RT) in 201 (36%) patients. Our analysis indicates that
8- and 20-week intervals failed to adequately distinguish reinfection from relapse. In addition,
living in a non-metropolitan area modified the effect of age on the risk of relapse. Where
molecular epidemiological data are not available, we suggest that applying an 8-week interval
to define recurrent CDI requires more consideration.

Introduction

© The Author(s) 2019. This is an Open Access
article, distributed under the terms of the
Creative Commons Attribution licence (http://
creativecommons.org/licenses/by/4.0/), which
permits unrestricted re-use, distribution, and
reproduction in any medium, provided the
original work is properly cited.

Clostridium difficile, recently renamed Clostridiodes difficile [1], is a Gram-positive anaerobic
bacillus and the most common cause of hospital-associated diarrhoea [2]. The Society of
Healthcare Epidemiology of America (SHEA) considers C. difficile infection (CDI) as one
of the most formidable infectious disease issues facing health care systems [3]. There has
also been increased interest in CDI as a result of multiple outbreaks in many countries with
a ‘hyper-virulent’ strain of C. difficile ribotype (RT) 027 [4]. Some states of the USA, the
UK and Australia currently have mandated surveillance programmes for CDI [5, 6]. In
Western Australia (WA), the Healthcare Infection Surveillance Western Australia (HISWA)
programme commenced surveillance of hospital-identified CDI (HI-CDI) in 2010 requiring
all acute care private and public hospitals to report HI-CDIs [7].
C. difficile has the ability to establish itself in the digestive system after the normal gut flora
have been altered, such as by exposure to antimicrobials. C. difficile spores colonise/infect
through the faecal–oral route [8]. CDI is a complex disease and, with its potential to cause
ongoing symptomatic disruptions to the normal flora of the digestive system, it is often difficult to determine if patients are experiencing a relapse in infection (originating from the same
strain that caused initial episode) or a reinfection (caused by a new strain or the same strain)
[9–11]. Discriminating relapse from reinfection is crucial for both clinical and surveillance
purposes. If infections cannot be correctly classified with a high degree of certainty, it also
becomes difficult to identify risk factors associated with different strains, evaluate treatment
effects and correctly quantify the true burden of CDI in the community [12].
Recommendations for determining CDI classification suggest that an interval of 8 weeks or
less after the onset of a previous episode (provided that symptoms from the index episode
resolve with or without therapy) indicates recurrent CDI [13–16]. If the time elapsed between
two episodes of CDI is >8 weeks, then the second episode is classed as a new infection as
opposed to recurrence of the original infection. These recommendations were developed as
interim guidelines by an international C. difficile Surveillance Working Group in 2007, and
variations have been adopted by many nations for surveillance purposes, including
Australia [17, 18]. However, some studies have suggested that an 8-week interval does not
allow sufficient discrimination of a recurrent infection as either a relapse or reinfection [5,
14, 19] and that an interval of 20 weeks might be optimal [12, 20].
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Fig. 1. Distribution of episodes of CDI.

Until whole genome sequencing (WGS) of C. difficile from
clinical samples becomes routine and can provide the highest
resolution data to determine strain relatedness, it is important
that current recommendations and definitions are continually
reviewed to ensure they have the ability to classify episodes of
CDI correctly. To date, the application of the 8-week interval

has not been tested for its performance in an Australian population. The objectives of this study were to: (1) use results from routinely performed ribotyping to test the accuracy of the 8-week
interval; (2) evaluate different proposed cut-offs, including the
20-week cut-off; and (3) identify risk factors associated with either
relapse or reinfection in the WA population.

Downloaded from https://www.cambridge.org/core. Edith Cowan University Library, on 21 Jun 2019 at 03:06:53, subject to the Cambridge Core terms of use, available at
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0950268819000499

Epidemiology and Infection

3

Table 1. Distribution of RTs in 551 isolates of C. difficile from recurrent infections
Ribotype
RT 014/020

Frequency

Per cent

Ribotype

Frequency

Per cent

361

32.76

RT 053

12

1.09

RT 002

99

8.98

RT 081

11

1.00

RT 056

45

4.08

QX 150

10

0.91

RT 012

41

3.72

RT 001

9

0.82

RT 046

29

2.63

RT 064

8

0.73

RT 070

28

2.54

RT 251

8

0.73

RT 054

27

2.45

RT 076

8

0.73

RT 018

24

2.18

RT 072

7

0.64

RT 005

23

2.09

RT 137

7

0.64

RT 017

21

1.91

RT 247

7

0.64

RT 015/193

20

1.81

RT 087

6

0.54

QX 076

19

1.72

RT 106

6

0.54

RT 010

18

1.63

RT 078

5

0.45

RT 103

17

1.54

RT 244

5

0.45

QX 024

14

1.27

Others

194

17.60

RT 043

13

1.18

Materials and methods
Setting and study population
This study was conducted in WA, one of the largest and most isolated health regions in the world. The state has an area of
2529875 km2 and a population of approximately 2.6 million, of
which over 75% reside in the metropolitan area of Perth, the
state capital (Australian Bureau of Statistics (ABS) 2017) [21].
Health services are delivered by a mix of government (public)
and private healthcare providers. The majority (86%) of all
acute care hospitals are government-run and clinical pathology
services delivered by PathWest Laboratory Medicine (WA)
(PathWest), the single public-sector pathology service provider.

Study design
A retrospective cohort study was performed utilising routinely collected health data on CDI events from PathWest and the
Communicable Disease Control Directorate, Department of
Health, WA. Ethical approvals for this research were obtained from
the Human Research Ethics Committees (HRECs) of the
Department of Health and The University of Western Australia
(approval numbers RGS0000000414 and RA/4/1/9124, respectively).
CDI cases recorded from October 2011 to July 2017 were
included in the study. Patients were excluded if they were <2
years of age, had only one episode ribotyped or if they were not
WA residents. Reinfections and relapses were derived from comparing the RTs causing initial and subsequent CDI episodes.
Demographic and other related variables were collected, such as
patient age, gender, postcode and hospital region where diagnosis
occurred. CDI cases were defined as having diarrhoea with a positive PCR for tcdB (see below). Tests were only performed on loose
or watery stool specimens, i.e. specimens that took the shape of
the container into which they were placed. For the purposes of
our study, we defined ‘relapse’ as ⩾2 episodes of CDI occurring

⩾1 week apart, both caused by the same RT, and ‘reinfection’
as infection with a new RT ⩾1 week after index CDI episode.
Postcodes were used to classify patients’ locations of residence
into two main areas: metropolitan (Perth) vs. non-metropolitan
using the Australian statistical geography standard remoteness
structure as defined by the ABS 2017 [22]. A non-metropolitan
area was defined as a remote, low population growth area, encompassing between 1% and 3% of the total Western Australian population (ABS 2007) [23].
Detection, culture and molecular typing of C. difficile
CDI cases were identified as having diarrhoeal stools and a positive tcdB PCR result on the BD MAX™ C.diff platform [24].
Routine PCR ribotyping of toxigenic C. difficile isolates commenced in October 2011. Culture and PCR ribotyping were performed as previously described and isolates were assigned
internationally recognised RTs or internal nomenclature prefixed
with ‘QX’ where international number was unknown [24].
Statistical analysis
Categorical variables were described as frequency counts and percentages, and continuous variables as medians and ranges.
Univariate logistic regression analysis was initially used to investigate odds ratios (ORs) associated with outcome of relapse vs.
reinfection. All variables were then assessed using a backward
elimination procedure to assist in determining the predictive variables to be included in the final logistic regression model. All statistical testing was two-tailed and P-value of <0.05 was considered
to be statistically significant. The C-statistic or the area under the
receiver operator characteristic (ROC) curve (AUC) was calculated to determine optimal cut-off values. All analyses were performed in SAS version 9.4 (Copyright © 2012–2017, SAS
Institute Inc., Cary, NC, USA).
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Table 2. Logistic regression model for risk of relapse vs. reinfection

Variable

Reinfection

Relapse

(n = 201)

(n = 350)

Time (56 days), median (1Q, 3Q)

59 (21, 190)

Age (20 years), median (1Q, 3Q)

66 (45, 80)

OR (95% CI)

P value

Adjusted OR (95%)*

P value

24 (13, 69)

0.89 (0.85–0.93)

<0.0001

0.89 (0.85–0.94)

<0.0001

71.5 (54, 82)

1.23 (1.06–1.43)

0.006

1.19 (1.02–1.39)

0.02

1.01 (0.71–1.43)

0.93

1.01 (0.70–1.46)

0.92

Gender–(%)
Male
Female

92 (46)

159 (45)

109 (54)

191 (55)

60 (30)

91 (26)

141 (70)

258 (74)

Ref

Ref

Residence–(%)
Non-metropolitan
Metropolitan
Missing

0 (0)

0.82 (0.56–1.21)

0.33

Ref

0.80 (0.50–1.29)

0.37

Ref

1 (0.2)

Location of diagnosis–(%)
164 (82)

292 (83)

1.12 (0.53–2.37)

0.75

1.07 (0.49–2.33)

0.84

Non-metropolitan hospital

25 (12)

39 (11)

0.98 (0.40–2.37)

0.97

1.70 (0.45–2.99)

0.74

Non-hospitalised/private pathology

12 (6)

19 (5)

⩽8 weeks

97 (48)

236 (67)

>8 weeks

104 (52)

114 (33)

⩽20 weeks

135 (67)

300 (86)

>20 weeks

66 (33)

50 (14)

Metropolitan hospital

Ref

Ref

8 week cut-off–(%)
2.21 (1.53–3.21)

<0.0001

—
—

Ref

20 week cut-off–(%)
2.93 (1.88–4.56)

<0.0001

—
—

Ref

Ribotype
RT 014/020

—

—

2.66 (1.77–4.01)

<0.0001

—

RT 002

—

—

3.86 (1.81–8.24)

0.0005

—

Significant findings (P < 0.05) in bold.
*Adjusted for age, gender, residence and time to second episode of CDI.

Results
Of 4612 patients who were identified with CDI between October
2011 and July 2017, 1471 (32%) were diagnosed with ⩾2 episodes
of CDI (Fig. 1). Overall, 1102 isolates from initial and second episodes of CDI were available from 551 patients, of which 350 (64%)
were classified as relapse and 201 (36%) were classified as reinfection. The most common RTs identified are presented in Table 1,
with RTs 014/020 (32%) and 002 (9%) the most dominant and significantly associated with the risk of relapse (Table 2).
Levels of discrimination between reinfections and relapses
were assessed for different cut-off intervals (Fig. 2 and Fig. 3).
Within the 8-week interval, the odds of relapse (vs. reinfection)
significantly exceeded those for infections arising beyond 8
weeks (OR 2.21, 95% CI 1.53–3.21; P < 0.0001). The odds of
relapse (vs. reinfection) within the 20-week interval were also significantly greater than those for infections arising beyond 20
weeks (OR 2.93, 95% CI 1.88–4.56; P < 0.0001) (Table 2).
Across a range of potential cut-offs, the 12-week interval was
associated with the highest ROC AUC of 0.61 (Fig. 3).
Multivariate analyses indicated that age, residence (metropolitan vs. non-metropolitan) and time from initial diagnosis of
CDI to second episode were significant risk factors for relapse.
The risk the second episode being caused by a different strain
increased by 11% on average for every increase of 56 days (8

weeks) following initial diagnosis of CDI to second episode (OR
1.11, 95% CI 1.06–1.17; P < 0.0001). There was a highly significant
statistical interaction between age and residence after adjusting for
time from initial diagnosis of CDI to the second episode (P <
0.0001) (Table 3). The risk of relapse decreased with age in
years among patients from non-metropolitan areas (OR 0.98,
95% CI 0.96–0.99; P = 0.03) whereas patients from metropolitan
areas had higher risk of relapse with age in years (OR 1.01, 95%
CI 1.01–1.02; P < 0.0001) (Table 3).

Discussion
In our study population, a total of 350 (64%) individuals experienced relapse compared with 201 (36%) with reinfection. This
finding is comparable with many previous studies [25–29] showing proportions of relapses between 51% and 88% compared with
12% and 41% for reinfections. These studies and the current
results suggest that the proportion of relapses is greater than
that for reinfections. Many early studies in distinguishing relapse
from reinfection found that reinfections can be misclassified as
relapses using conventional laboratory techniques [30, 31].
O’Neill et al. (1991), using restriction enzyme analysis of chromosomal DNA, found 75% of apparent relapses were caused by a
new strain. It is currently assumed that employing a more
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Fig. 2. Performance of the 8- and the 20-week cut-off intervals in separating reinfections from relapses. (Reinfections) occurred within the 8- and 20-weeks intervals. Relapses occurred outside the 8- and the 20-weeks intervals.

Table 3. Interactions in the logistic regression model
Relapse
Variable

Adjusted OR (95% CI)

Residence− × age

P value
<0.0001

Non-metro × age = (1 year)

0.98 (0.96–0.99)

0.03

Metro × age = (1 year)

1.01 (1.01–1.02)

<0.0001

0.89 (0.85–0.93)

<0.0001

Time units (56) days
Significant findings (P < 0.05) in bold.

Fig. 3. Cut-off intervals to discriminate CD reinfection from relapse. Each cut-off is
used to predict reinfections. The areas under the ROC curve (AUC) indicate that
the discriminatory power of all the cut-offs is not effective. The 12-week cut-off is
associated with the highest AUC.

discriminatory typing technique such as WGS would likely class
some relapses as reinfections, given its ability to detect withinstrain diversity [32]. The most common strain associated with

relapse here, RT 014, has been divided into many sub-lineages
using WGS [33].
Our findings suggest that use of various cut-off periods could
result in misclassification of patients with recurrent episodes of
CDI. Various studies [5, 14, 20, 25, 28, 34] support our findings
that an 8-week cut-off is not effective in discriminating between
reinfection and relapse. A 20-week cut-off, which was recently associated with an ROC AUC of 74% [12] implying good discriminative
power, has been recommended. However, our study found a ROC
AUC of only 59% for a 20-week cut-off, while a 12-week interval
was associated with the highest AUC of 61%. The 12-week cut-off
has been adopted by many health centres in the USA [35].
Risk factors for recurrent CDI episodes are not well understood, but can include treatment failure or continuous exposure
to the same antecedents that resulted in the initial episode. Our
findings of a significant difference in the risk of reinfection vs.
relapse between younger and older patients are supported by
other studies [26, 36]. We observed that the risk of reinfection
tended to be higher among older patients from non-metropolitan
areas, whereas it was lower among younger patients from the
metropolitan area. Conversely, the risk of relapse decreased with
age among patients from non-metropolitan areas and yet
increased with age among those from the metropolitan area. In
non-metropolitan WA, residents (such as pastoralists) are more
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likely to fall within older demographic groups and more commonly reside in proximity to production animals which are
known reservoirs of C. difficile [37–42]. Risk of reinfection may
also relate to changes in immunity and gut microflora as people
advance in age or to differences in exposure to environmental
sources. Younger patients were more likely to experience relapse
in the metropolitan area, possibly because the relatively limited
diversity of C. difficile RTs in urban environments makes reinfection with a novel strain less likely.
There were a number of strengths in our study design, including a relatively large sample size and consistency of laboratory
methods over a long period using a single public sector pathology
service. This study is the first in Australia to characterise relapse
vs. reinfection using the technique of PCR ribotyping. To our
knowledge, our study represents a first attempt in Australia to
compare the risk of relapse vs. reinfection in patients from nonmetropolitan areas to those from metropolitan areas.
There were some potential limitations in our study. First, we
were limited by the restricted number of available risk factors
included in the dataset. Other factors – such as the presence of
comorbid medical conditions and the history of antibiotic use –
might confound the true relationship between the risk of reinfection or relapse with time, age and residence. Second, we were
unable to ascertain from the data whether the initial episode
was resolved or if diarrhoeal symptoms were ongoing. ‘Test for
cure’ is not performed by our laboratory and only diarrhoeal specimens are tested for CDI. We allowed for a period of ⩾1 week
after initial episode to define recurrent episodes as relapse or
reinfection based on comparing RTs. Clinical practice guidelines
recommend a period of >14 days from initial infection to second
episode to be defined as recurrent CDI [43]. However, we identified 27 cases where a new RT was isolated within 7–14 days of initial diagnosis. This is of great interest because it suggests study
subjects are coming into contact with C. difficile on a regular
basis. We have shown that C. difficile is increasingly prevalent
in our local outdoor environment, for example, contaminating
roll-out lawn [44] and retail vegetables [45] in WA. Finally,
PCR ribotyping is not as powerful a tool as WGS for distinguishing discrete strains or their sub-lineages [32].
In conclusion, this study suggests that 8- and 20-week cut-offs
both failed to reliably distinguish reinfection from relapse. Our
results have significant implications for public health strategies
aimed at controlling infection by C. difficile. For patients with
relapse, new treatment plans may be assigned, such as faecal
microbiota transplantation or courses of newer agents such as
fidaxomicin [46, 47]. In comparison, reinfection might indicate
some failure in applied infection prevention and control strategies
in healthcare facilities, and could suggest that alternative disinfection measures might need to be considered [48]. We suggest that
current definitions utilising 8- or 20-week intervals to distinguish
between relapse and reinfection require reconsideration.
Repeating these analyses using WGS is warranted in the future.
Author ORCIDs.
M. Al-Fayyadh, 0000-0003-1481-6046; D. A. Collins,
0000-0001-6754-9290.
Conflict of interest. None.
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